Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, FUSN shareholders are expected to receive $21.00 in cash plus one non-tradable CVR worth up to $3.00 per share they own.

To receive more information regarding the investigation of Fusion Pharmaceuticals Inc. please fill out the form below.